Gold prices hit 2-week high as Trump-Fed feud escalates with Cook firing
Terrence A. Duffy, Chairman and CEO of CME Group Inc. (NASDAQ:CME), sold 30,000 shares of the company’s Class A common stock on March 11, 2025. This transaction, valued at approximately $7.78 million, was executed at a weighted average price of $259.18 per share, with the sale prices ranging from $259.00 to $259.26. The sale comes as CME trades near its 52-week high of $262.51, with the stock delivering a robust 26.6% return over the past year. According to InvestingPro analysis, the stock currently appears slightly overvalued relative to its Fair Value. Following this sale, Duffy retains ownership of 53,205 shares of CME Group stock. CME Group, headquartered in Chicago, operates as a leading global derivatives marketplace with a market capitalization of $94 billion. The company maintains strong financial health, earning a "GREAT" overall score from InvestingPro, which highlights its 23-year track record of consistent dividend payments and impressive 100% gross profit margin. For deeper insights into CME’s valuation and financial metrics, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, CME Group announced the launch of new Bloomberg Commodity Subindex futures, set to begin trading on March 31, pending regulatory approval. These futures will cover sectors such as Agriculture, Grains, Livestock, Petroleum, Energy, All Metals, and Precious Metals, providing investors with additional tools for risk management. Keefe, Bruyette & Woods maintained their Market Perform rating on CME Group, with a price target of $257, noting that the company’s average daily volume for February was tracking above estimates. Citi analysts revised their price target for CME Group to $265, citing a 12% year-over-year increase in average daily volume and strong sector performance in rate contracts, agricultural commodities, and metals.
Keefe also slightly raised their price target to $257 following an earnings report that exceeded expectations, attributing the outperformance to higher transaction revenues and increased market data fees. UBS lifted its price target to $290, maintaining a Buy rating, highlighting expectations for strong trading volumes and revenue growth from fee increases. UBS also mentioned potential share buybacks as a catalyst for future stock performance. These developments reflect CME Group’s strategic positioning in the market and its efforts to enhance its product offerings and customer base.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.